Cargando…

MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon

BACKGROUND: MET amplification appears to be a predictive biomarker for MET inhibition. Prior studies reported a MET amplification rate of 9–18% in metastatic colorectal cancer (mCRC) but do not differentiate increased gene copy numbers due to chromosomal level aberrations from focal gene amplificati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raghav, Kanwal, Morris, Van, Tang, Chad, Morelli, Pia, Amin, Hesham M., Chen, Ken, Manyam, Ganiraju C., Broom, Bradley, Overman, Michael J., Shaw, Kenna, Meric-Bernstam, Funda, Maru, Dipen, Menter, David, Ellis, Lee M., Eng, Cathy, Hong, David, Kopetz, Scott
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342368/ https://www.ncbi.nlm.nih.gov/pubmed/27421137 http://dx.doi.org/10.18632/oncotarget.10559

Ejemplares similares

Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer
por: Sarshekeh, Amir Mehrvarz, et al.
Publicado: (2017)

Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer
por: Davis, Jennifer S., et al.
Publicado: (2022)

Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer
por: Lee, Michael S, et al.
Publicado: (2016)

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors
por: Tang, Chad, et al.
Publicado: (2013)

Autologous humanized mouse models to study combination and single-agent immunotherapy for colorectal cancer patient-derived xenografts
por: Kanikarla Marie, Preeti, et al.
Publicado: (2022)

Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin
por: Overman, Michael J., et al.
Publicado: (2016)

Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications
por: Dumbrava, Ecaterina E. Ileana, et al.
Publicado: (2019)

FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma
por: Korphaisarn, Krittiya, et al.
Publicado: (2017)

Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma
por: Korphaisarn, Krittiya, et al.
Publicado: (2019)

Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature
por: Korphaisarn, Krittiya, et al.
Publicado: (2017)

Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer
por: Kopetz, Scott, et al.
Publicado: (2014)

iBAG: integrative Bayesian analysis of high-dimensional multiplatform genomics data
por: Wang, Wenting, et al.
Publicado: (2013)

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6
por: Sorokin, Alexey V., et al.
Publicado: (2022)

Clinical utility of circulating cell-free DNA in advanced colorectal cancer
por: Pereira, Allan A. Lima, et al.
Publicado: (2017)

Targeting translation initiation in breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2014)

Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy
por: Kanikarla-Marie, Preeti, et al.
Publicado: (2018)

Whole Genome Sequencing in Cancer Clinics
por: Chen, Ken, et al.
Publicado: (2014)

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic
por: Dembla, Vikas, et al.
Publicado: (2018)

Personalized cancer therapy—leveraging a knowledge base for clinical decision-making
por: Dumbrava, Ecaterina Ileana, et al.
Publicado: (2018)

Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers
por: Kopetz, Scott, et al.
Publicado: (2019)

Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial
por: Raghav, Kanwal P, et al.
Publicado: (2022)

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
por: Jardim, Denis L. Fontes, et al.
Publicado: (2014)

KPP: KEGG Pathway Painter
por: Manyam, Ganiraju, et al.
Publicado: (2015)

Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations
por: Somaiah, Neeta, et al.
Publicado: (2018)

Implications of Intratumor Heterogeneity on Consensus Molecular Subtype (CMS) in Colorectal Cancer
por: Chowdhury, Saikat, et al.
Publicado: (2021)

Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review
por: Shen, Chan, et al.
Publicado: (2022)

Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics
por: Parseghian, Christine, et al.
Publicado: (2023)

The rapamycin-regulated gene expression signature determines prognosis for breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2009)

An efficient algorithm for systematic analysis of nucleotide strings suitable for siRNA design
por: Baranova, Ancha, et al.
Publicado: (2011)

Integrative Analysis of mRNA, microRNA, and Protein Correlates of Relative Cerebral Blood Volume Values in GBM Reveals the Role for Modulators of Angiogenesis and Tumor Proliferation
por: Rao, Arvind, et al.
Publicado: (2016)

Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer
por: Raghav, Kanwal, et al.
Publicado: (2020)

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
por: Liu, X., et al.
Publicado: (2015)

Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer
por: Chen, Z-Y, et al.
Publicado: (2015)

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer
por: Oddo, Daniele, et al.
Publicado: (2017)

FuncPEP: A Database of Functional Peptides Encoded by Non-Coding RNAs
por: Dragomir, Mihnea P., et al.
Publicado: (2020)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Yoshimura, Katsuhiro, et al.
Publicado: (2021)

Functional consequence of the MET-T1010I polymorphism in breast cancer
por: Liu, Shuying, et al.
Publicado: (2014)

Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery
por: Uemura, Marc, et al.
Publicado: (2017)

Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel
por: Shen, Chan, et al.
Publicado: (2016)

Identification of KRAS(G12C) Mutations in Circulating Tumor DNA in Patients With Cancer
por: Thein, Kyaw Z., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_aqtcgimld6qkp36g68qjc8402p